Cibus, Inc. Announces Proposed Public Offering of Class A Common Stock
Rhea-AI Summary
Cibus (Nasdaq: CBUS) announced a proposed underwritten public offering of its Class A common stock on Jan 28, 2026. BTIG is sole underwriter and may receive a 30-day option to buy up to 15% additional shares. Proceeds are intended for working capital, development of rice weed-management traits, and professional expenses. Certain board members indicated non-binding interest to purchase shares. The offering is made under an effective Form S-3 shelf registration and is subject to market conditions; final size, price, and timing remain uncertain.
Positive
- Underwriter option up to 15% of offering
- Proceeds earmarked for rice weed-management trait development
- Intended use includes working capital and advisory expenses
Negative
- Related persons indicated non-binding interest to purchase shares
- Offering is subject to market conditions; size and timing uncertain
News Market Reaction
On the day this news was published, CBUS declined 2.22%, reflecting a moderate negative market reaction. Argus tracked a peak move of +17.6% during that session. Argus tracked a trough of -13.5% from its starting point during tracking. Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $2M from the company's valuation, bringing the market cap to $109M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
CBUS is up about 4.65% ahead of its proposed offering, while key biotech/ag peers mostly fell (e.g., ACET -1.61%, IGMS -2.31%, VANI -3.5%), suggesting a stock-specific move rather than a sector trend.
Previous Offering Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jun 09 | Offering closing | Negative | -0.6% | Closing of $27.5M equity financing through public offering of common stock. |
| Jun 05 | Offering pricing | Negative | -34.3% | Pricing of $27.5M common stock offering at $1.75 per share. |
| Jun 04 | Offering proposed | Negative | -34.3% | Announcement of proposed public offering with chairman indicating purchase interest. |
| Jan 21 | Registered direct deal | Negative | -5.7% | Announcement of $22.6M registered direct offering with warrants and repriced existing warrants. |
| Sep 18 | Offering pricing | Negative | -28.9% | Pricing of $12.0M public offering of 3M shares at $4.00 per share. |
Prior CBUS equity offerings have typically seen negative next-day price reactions, indicating a history of dilution concerns being priced in quickly.
Over the past year, Cibus has executed multiple equity financings, including public and registered direct offerings, often tied to funding its weed management traits in Rice and broader productivity pipeline. Historical offering-related headlines on Sep 18, 2024, Jan 21, 2025, and the June 4–9, 2025 sequence all saw negative price reactions, reinforcing a pattern of shareholder sensitivity to dilution. Today’s proposed offering fits this ongoing capital-raising trajectory.
Historical Comparison
In the past, CBUS offering-related announcements produced average moves of about 20.77%, usually downside. The current proposed offering reaction appears comparatively moderate versus that history.
The company has repeatedly used equity offerings since 2024 to fund development of rice weed management traits and broader productivity traits, showing a consistent reliance on public capital raises.
Market Pulse Summary
This announcement details a proposed underwritten sale of Class A common stock, with a 30-day option for the underwriter to buy up to an additional 15% of the shares. The company cites working capital and continued development of weed management traits in Rice as key uses of proceeds. Historically, CBUS has relied on repeated equity raises to fund its pipeline and operations, so investors may focus on offering size, pricing, insider participation, and how efficiently fresh capital is deployed.
Key Terms
underwritten public offering financial
prospectus supplement regulatory
base prospectus regulatory
AI-generated analysis. Not financial advice.
SAN DIEGO, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural technology company that develops and licenses plant traits to seed companies, today announced that it intends to offer shares of its Class A common stock, par value
BTIG, LLC is acting as the sole underwriter for the Offering.
Cibus currently intends to use the net proceeds from the Offering for working capital and general corporate purposes, including to fund further development of its weed management traits in Rice and to pay accrued professional expenses for advisory services.
The securities will be offered pursuant to an effective shelf registration statement on Form S-3 (File No. 333-273062), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on June 30, 2023, as amended on October 25, 2023, and declared effective by the SEC on October 27, 2023. A prospectus supplement describing the terms of the Offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Copies of the prospectus supplement and the accompanying base prospectus, when available, may be obtained from BTIG, LLC, at 65 East 55th Street, New York, New York 10022 or by telephone at (212) 593-7555, or by email at ProspectusDelivery@btig.com. Before investing in this Offering, interested parties should read in their entirety the preliminary prospectus supplement and the accompanying prospectus and the other documents that Cibus has filed with the SEC that are incorporated by reference in such preliminary prospectus supplement and the accompanying prospectus, which provide more information about Cibus and such Offering.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Cibus
Cibus is a leader in developing traits (characteristics) that address critical productivity, yield and sustainability challenges. Cibus’ proprietary high-throughput gene-editing technologies drive its long-term focus on productivity traits for farmers for the major global row crops. Cibus is not a seed company. It is a technology company that uses its gene editing technologies to develop plant traits at a fraction of the time and cost of conventional breeding and to license them to customers in exchange for royalties.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as “anticipates,” “believes,” “continue,” “estimates,” “expects,” “intends,” “may,” “might,” “plans,” “predicts,” “projects,” “should,” “targets,” “will,” or the negative of these terms and other similar terminology. Forward-looking statements in this press release include, but are not limited to, statements regarding the anticipated Offering and the expected use of the proceeds therefrom. Completion of the Offering is subject to numerous factors, many of which are beyond Cibus’ control, including, without limitation, market conditions, failure to satisfy customary closing conditions and the risk factors and other matters set forth in the prospectus supplement and accompanying prospectus included in the registration statement and the documents incorporated by reference therein. You are cautioned not to place undue reliance on any forward-looking statements, which are based only on information currently available to it when, and speak only as of the date, such statement is made. Cibus does not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by law.
CIBUS CONTACTS:
INVESTOR RELATIONS
Jeff Sonnek – ICR
jeff.sonnek@icrinc.com
MEDIA RELATIONS
media@cibus.com
Colin Sanford
colin@bioscribe.com
203-918-4347
FAQ
What is Cibus (CBUS) proposing in the Jan 28, 2026 offering?
Who is the underwriter for Cibus (CBUS) and what option exists?
How does Cibus (CBUS) plan to use net proceeds from the offering?
Are Cibus board members buying shares in the CBUS offering?
Where can investors find the Cibus (CBUS) prospectus for the offering?
Is the Cibus (CBUS) offering guaranteed to occur and when will it close?
